Pillars of growth
Heavy bet for R&D
as a future
growth engine
Heavy bet on R&D
as a future
growth engine
Biosimilars
A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.
Pharmaceutical products
Diversified portfolio of innovative own and licensed products protected by patents.
Low Molecular Weight Heparin
ROVI's principal product, a low-molecular-weight heparin developed in-house.
CDMO
High production capacity with four the manufacturing plants for prefilled syringes and oral solid forms.
Rovi in figures
817.7 Mn€
Operatig revenuesin 2022
264.0 Mn€
Sales for the Heparin Division in 2022(+9% vs 2021)
+90 countries
LMWH presence through strategic alliances with international partners
7 plants
For the third party, own and Investigational drug manufacture
403.5 Mn€
CDMO Sales in 2022 (+52% vs 2021)
42,85%
Porcentage of women on the Boards of Directors
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Last news on Rovi
Last annual report
Annual report 2022
Last regular
public information